BridgeBio Pharma Gross Margin 2018-2025 | BBIO
Current and historical gross margin for BridgeBio Pharma (BBIO) over the last 10 years. The current gross profit margin for BridgeBio Pharma as of March 31, 2025 is %.
| BridgeBio Pharma Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2025-03-31 |
$0.13B |
$0.12B |
95.31% |
| 2024-12-31 |
$0.22B |
$0.22B |
98.65% |
| 2024-09-30 |
$0.22B |
$0.22B |
99.08% |
| 2024-06-30 |
$0.22B |
$0.22B |
99.09% |
| 2024-03-31 |
$0.22B |
$0.22B |
98.63% |
| 2023-12-31 |
$0.01B |
$0.01B |
60.00% |
| 2023-09-30 |
$0.01B |
$0.01B |
60.00% |
| 2023-06-30 |
$0.01B |
$0.00B |
50.00% |
| 2023-03-31 |
$0.08B |
$0.08B |
96.15% |
| 2022-12-31 |
$0.08B |
$0.07B |
94.87% |
| 2022-09-30 |
$0.09B |
$0.08B |
94.38% |
| 2022-06-30 |
$0.09B |
$0.09B |
93.41% |
| 2022-03-31 |
$0.07B |
$0.07B |
92.96% |
| 2021-12-31 |
$0.07B |
$0.07B |
95.65% |
| 2021-09-30 |
$0.06B |
$0.06B |
98.21% |
| 2021-06-30 |
$0.06B |
$0.06B |
100.00% |
| 2020-09-30 |
$0.02B |
$0.02B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.397B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
